DarioHealth Launches Integrated Diabetes Digital Health Solution Including Version 4.1 of Its Award-winning Dario App and DarioEngage Patient Coaching Platform

    New Capabilities Aim to Enable Higher Patient Adherence and Further Improve Clinical Outcomes

    Oct 25, 2018

    CAESAREA , Israel, Oct. 25, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today the launch of version 4.1 of its award-winning Dario® App for the Dario Blood Glucose Monitoring System, part of the DarioHealth digital diabetes data management platform. The app, which is available both direct-to-consumer and through healthcare providers, is now fully integrated with the DarioEngage patient management and coaching platform, which serves the healthcare provider market.  

    DarioHealth Logo

    "The very compelling clinical data we presented at the American Diabetes Association (ADA) in June made it clear that the combination of long term use of the Dario Blood Glucose Monitoring System and higher levels of user engagement results in sustainable user behavior changes and associated positive clinical outcomes. Based on these data, we have added features to the Dario® App v4.1 and fully integrated the app with our DarioEngage platform, creating a unified diabetes digital health platform that we believe is the most advanced solution of its kind," stated Erez Raphael, Chief Executive Officer of DarioHealth.

    New features of the integrated Dario App v4.1 and DarioEngage include:

    • Enhanced in-app acquisition capabilities, enabling users who download the app to more easily become device and service subscribers. Annual subscriptions are offered to incentivize long-term use which has shown to be associated with positive clinical outcomes and average cost savings of $230 per patient, per month estimated using typical healthcare costs. The improvement in average blood glucose levels and hyperglycemic events reported in clinical papers submitted to the ADA was based on a study of 17,000 users of the Dario Blood Glucose Monitoring System.
    • DarioEngage enables one-click scheduling for visits and calls between healthcare providers and patients. This solves the pain of scheduling and extends the reach of care providers who wish to schedule treatment appointments with patients. Through ease of use and seamless connectivity, DarioHealth is establishing a new industry standard for scheduling with this capability.
    • Holistic integrated solution that integrates the DarioEngage platform with the Dario Blood Glucose Monitoring System App, creating efficiency in the day-to-day work of the clinician. The integrated platform provides the right information, at the right time, in the right context. The DarioEngage patient management platform gives healthcare providers the ability to access data from patients' apps in real time. Caregivers are now empowered with the option of using digital interactions through chat, SMS, in-app notices, and more.

    About DarioHealth Corp.

    DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital health company serving its users with dynamic mobile health solutions. In today's day and age, knowledge of health and treatment is being democratized, and we believe people deserve to know everything about their own health and have the best tools to manage their condition. DarioHealth employs a revolutionary approach whereby harnessing big data, we have developed a novel method for chronic disease data management, empowering people to analyze and personalize self-diabetes management in a totally new way without having the disease slow them down. DarioHealth has a commercial office in New York with an R&D center in Caesarea, Israel. For more information, visit http://mydario.investorroom.com/.

    Cautionary Note Regarding Forward-Looking Statements

    This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, when the Company describes the benefits and future potential of its products, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

    DarioHealth Corporate Contact: Joao Mendes-Roter, VP Marketing, joao@mydario.com, 1-914-775-5548

    SOURCE DarioHealth Corp.


    print email rss